secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMPACT BIOMEDICAL INC. (IBO)
CIK:        0001834105
Form:       8-K
Filed at:   2026-10-09T20:58:52+00:00
Accession:  0001493152-26-046572
Event type: other_material
Sentiment:  neutral
Materiality: 0.78
Item codes: 5.03, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Impact BioMedical completes 1-for-12.62 reverse stock split effective September 23, 2026
--------------------------------------------------------------------------------

- Reverse split ratio is 1-for-12.62, effective 12:01 A.M. EST on September 23, 2026; IBO began trading split-adjusted on NYSE American.
- Outstanding shares fell from about 107.8 million to about 8.6 million; authorized shares, $0.001 par value, and voting rights were unchanged.
- New CUSIP is 45259L304; Equiniti Transfer & Trust Company is exchange agent; no fractional shares were issued, with fractional holders receiving one full share.
- Board approved reverse split on November 24, 2025, and majority stockholders approved it on December 30, 2025, with CEO given discretion on ratio.
- Nevada Secretary of State clerical error delayed the file-stamped Amendment until October 6, 2026, after effectiveness on September 23, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1834105/000149315226046572/0001493152-26-046572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1834105/000149315226046572/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-046572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer